Work

Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1)

Year: 2019

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-019-00856-7

Authors: Ruud van der Noll, Agnes Jager, Joo Ern Ang, Serena Marchetti, Marja W. J. Mergui-Roelvink, Martijn P. Lolkema, Maja J. A. de Jonge, Diane A. van der Biessen, Andre T. Brunetto, Hendrik-Tobias Arkenau, Ilian Tchakov, Jos H. Beijnen, Johann S. de Bono, Jan H. M. Schellens

Institutions: The Netherlands Cancer Institute, Erasmus MC, Erasmus MC Cancer Institute, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, AstraZeneca (United Kingdom), Eisai (United Kingdom), Utrecht University

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: AstraZeneca

OpenAlex ID: W2982510276

FWCI: 0.522

Cites: 50

Cited by: 16

Related to: 10